This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALXN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
Stock Market News for Jan 12, 2021
by Zacks Equity Research
Benchmarks declined from record highs on Monday as investors weighed impact of rise in coronavirus cases and ongoing political turmoil on economic growth.
BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy
by Zacks Equity Research
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients with hemophilia A.
ALXN or BMRN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. BMRN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
4 Biotechs That Could Be Potential Acquisition Targets in 2021
by Zacks Equity Research
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate
by Zacks Equity Research
Pfizer (PFE) doses the first participant in the late-stage BASIS study, currently investigating marstacimab to address severe hemophilia A or B with or without inhibitors.
Intercept's (ICPT) Q3 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a wider loss but beats on sales in the third quarter of 2020.
BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.
BioMarin Pharmaceutical (BMRN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 116.00% and 3.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Pharmaceutical (BMRN) Stock Moves -0.84%: What You Should Know
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) closed at $76.88 in the latest trading session, marking a -0.84% move from the prior day.
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q3 Earnings Expected to Decline
by Zacks Equity Research
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) Gets FDA Approval for Higher Dose of Palynziq
by Zacks Equity Research
The FDA approves higher dose (60 mg) of BioMarin's (BMRN) Phenylketonuria drug Palynziq injection. The regulatory nod includes the addition of longer-term efficacy data on Palynziq's label.
Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH
by Zacks Equity Research
Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.
Zacks.com featured highlights include: Vail, Las Vegas Sands, BioMarin and Allegiant
by Zacks Equity Research
Zacks.com featured highlights include: Vail, Las Vegas Sands, BioMarin and Allegiant
BioMarin Initiates Gene Therapy Study for Phenylketonuria
by Zacks Equity Research
BioMarin (BMRN), a leader in the phenylketonuria segment, initiates development of its first gene therapy for treating the rare genetic enzyme deficiency disorder.
Stay Away From These 4 Toxic Stocks to Avoid Losses
by Rimmi Singhi
Investors who can figure out the overpriced toxic stocks and shun them at the right time are the ones that are likely to benefit.
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN
by Zacks Equity Research
Zacks.com featured highlights include: ILMN, PFSW, CCJ and BMRN
These 4 Stocks Could Be Toxic for Your Portfolio
by Rimmi Singhi
Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.
BioMarin Pharmaceutical (BMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) closed at $76 in the latest trading session, marking a +0.21% move from the prior day.
BioMarin (BMRN) Down 34.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.